Paller Amy S, Singh Rakesh, Cloutier Martin, Gauthier-Loiselle Marjolaine, Emond Bruno, Guérin Annie, Ganguli Arijit
J Drugs Dermatol. 2018 Feb 1;17(2):187-194.
While psoriasis (Ps) is mainly characterized as an adult disease, it can also develop during childhood. However, prevalence estimates of pediatric psoriasis in the United States (US) are lacking.
To assess the 2015 annual prevalence of Ps and moderate-to-severe Ps in pediatric individuals in the US.
This is a retrospective study based on a large administrative insurance claims database in the US.
Data were extracted from the Truven Health Analytics MarketScan® Commercial Claims and Encounters database, which covers over 60 million individuals with employer-provided health insurance across the US.
Over 4.3 million of individuals continuously enrolled in their healthcare plan in 2015 and under 18 years of age were included in the study. Intervention(s) for Clinical Trials or Exposure(s) for Observational Studies: Not applicable. Main Outcome(s) and Measure(s): Ps was defined based on medical claims with a diagnosis of Ps (ICD-9-CM: 696.1); moderate-to-severe Ps was defined based on medical or pharmacy claims for a systemic treatment (biologic, conventional systemic, or phototherapy) for Ps. Overall and age- and gender-stratified prevalence was estimated for both Ps and moderate-to-severe Ps.
The prevalence of Ps was estimated at 128 cases per 100,000 individuals (95% CI: 124-131), that of moderate-to-severe Ps at 16 cases per 100,000 individuals (95% CI: 15-17) in 2015. For both Ps and moderate-to-severe Ps, prevalence estimates were numerically higher in females than in males (146 per 100,000 vs. 110 per 100,000 and 17 per 100,000 vs. 15 per 100,000) and increased with age, ranging from 30 per 100,000 in the 0-3 year old group to 205 per 100,000 in the 12-17 year old group.
This study provides robust estimates of the prevalence of pediatric Ps that can inform decisions pertaining to the management of pediatric patients with Ps. J Drugs Dermatol. 2018;17(2):187-194.
虽然银屑病（Ps）主要被视为一种成人疾病，但它也可能在儿童期发病。然而，美国缺乏儿童银屑病患病率的估计数据。
评估2015年美国儿童银屑病及中重度银屑病的年患病率。
这是一项基于美国大型行政管理保险理赔数据库的回顾性研究。
数据取自Truven Health Analytics MarketScan®商业理赔与诊疗数据库，该数据库涵盖美国超过6000万拥有雇主提供医疗保险的人群。
2015年持续参保其医疗保健计划且年龄在18岁以下的超过430万人纳入研究。临床试验干预或观察性研究暴露：不适用。主要结局和测量指标：银屑病根据诊断为银屑病的医疗理赔定义（国际疾病分类第九版临床修订本：696.1）；中重度银屑病根据银屑病全身治疗（生物制剂、传统全身性药物或光疗）的医疗或药房理赔定义。对银屑病及中重度银屑病均估计了总体患病率以及按年龄和性别分层的患病率。
2015年银屑病患病率估计为每10万人中有128例（95%置信区间：124 - 131），中重度银屑病患病率为每10万人中有16例（95%置信区间：15 - 17）。对于银屑病及中重度银屑病，患病率估计在数值上女性高于男性（每10万人中146例对110例以及每10万人中17例对15例），且随年龄增加，从0 - 3岁组的每10万人中30例到12 - 17岁组的每10万人中205例不等。
本研究提供了可靠的儿童银屑病患病率估计，可为儿童银屑病患者的管理决策提供参考。《皮肤药物杂志》。2018；17(2)：187 - 194。
